Connect with us

Technology

Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers

Published

on

UPPSALA, Sweden, Oct. 6, 2026 /PRNewswire/ — Beactica Therapeutics AB, a Swedish precision medicine company, today announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which is aimed at developing novel therapies for a range of aggressive, difficult-to-treat solid tumours, including cancers where resistance to existing treatments remains a major clinical challenge.

BEA-28 is a first-in-class small molecule targeted degrader of the TEAD transcription factors, key effectors of the Hippo-YAP/TAZ pathway. Rather than blocking a binding pocket, BEA-28 removes the TEAD proteins and all their functions – an approach suited to cancers where pathway activity drives tumour growth or treatment resistance. In preclinical studies, BEA-28 showed robust tumour regressions at well-tolerated doses, and restored sensitivity to KRAS inhibitors in resistant models. The programme advances a biomarker-led, combination strategy, with a high unmet need cancer as the lead indication.

“Selecting BEA-28 as a preclinical candidate reflects the strength of our TEAD degrader programme and our confidence in the compound’s differentiated profile. The compound has met all predefined success criteria for this stage, and we believe it has the potential to address several hard-to-treat cancers through a clear biomarker-led strategy.” said Dr Per Källblad, CEO of Beactica Therapeutics. “By moving this specific molecule into final candidate validation, we are executing on our mission to transition this program rapidly toward the clinic.”

BEA-28 was selected after meeting predefined success criteria covering chemistry, in vitro and in vivo pharmacology, ADME and pharmacokinetic properties. The molecule will now advance into comprehensive candidate validation, including non-regulatory (pre-GLP) toxicology, scale-up chemistry, and advanced formulation profiling. Studies formally supporting IND-enabling requirements will be initiated following candidate drug nomination.

About BEA-28

BEA-28, closely related to P65-047, is a first-in-class, cereblon-recruiting small molecule degrader of the TEAD transcription factors, generated using Beactica’s Eclipsor™ platform and developed to shut down Hippo-YAP/TAZ-TEAD pathway activity implicated in tumour growth, immune evasion and resistance to targeted therapies. In preclinical studies, BEA-28 has shown deep responses in selected high-need lineages within a broad cancer cell line panel and reversed acquired resistance to KRAS-inhibitor treatment in cellular models. In vivo, BEA-28 achieved robust TEAD degradation in target tissue and induced tumour regression in xenograft models of mesothelioma and KRAS-mutant lung cancer at well-tolerated, once-daily doses. Beactica is developing BEA-28 alongside a biomarker-driven patient selection strategy intended to identify the tumours most likely to respond, with lead combination strategies planned in a non-mesothelioma high unmet need cancer alongside checkpoint inhibitors, and in KRAS-driven cancers alongside KRAS inhibitors. BEA-28 is investigational and has not been approved anywhere globally; its efficacy and safety in humans have not been established.

About Beactica Therapeutics

Beactica Therapeutics AB is a privately held precision medicine company with a pipeline of novel small molecule therapeutics aimed at treating diseases with significant unmet medical need. Beactica’s approach is centred around the Eclipsor™ platform that enables the efficient development of allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.

Forward-looking statements

This press release contains forward-looking statements regarding Beactica’s development plans for BEA-28, including the candidate drug nomination and subsequent preclinical and regulatory progression. Such statements reflect current expectations, and actual results may differ materially. Beactica undertakes no obligation to update them except as required by law.

Beactica Therapeutics Contact

Per Källblad M.Sc. Ph.D.
CEO
per.kallblad@beactica.com
Tel: +46 18 56 08 80

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/beactica-therapeutics-ab/r/beactica-therapeutics-selects-bea-28-as-a-preclinical-candidate–a-first-in-class-tead-degrader-for-,c4404650

The following files are available for download:

https://mb.cision.com/Main/17268/4404650/4302484.pdf

261006_BeacticaTx_BEA-28_Selection_Eng

 

View original content:https://www.prnewswire.com/news-releases/beactica-therapeutics-selects-bea-28-as-a-preclinical-candidate-a-first-in-class-tead-degrader-for-biomarker-selected-cancers-302899418.html

SOURCE Beactica Therapeutics AB

Continue Reading

Technology

Wiremind raises €35 Million in First-Ever Funding Round

Published

on

By

The French scale-up will accelerate its international expansion and position itself as the go-to technology partner for transport operators and the live events ticketing industry

PARIS, 6 October 2026 /PRNewswire/ — Wiremind today announced it has raised €35 million from three new investors: IronWave (formerly Wendel Growth), Bpifrance Investissement (via its Large Venture fund) and Seaya Andromeda. Co-founders Colin Girault-Matz (CEO) and Charles Pierre (CTO) remain majority shareholders and retain control of the business.

Profitable since its founding in 2014, Wiremind develops revenue management, inventory and distribution software for passenger transport operators and event organisers. In 2025, its revenue grew by 67% while adding 23 new clients. Today, it serves over 80 clients across the product suite.

After 12 years of self-financed growth, Wiremind will use the new capital to fuel two strategic priorities:

International expansion: Wiremind will continue its growth in South America and increase its presence in the Middle East and APAC transport markets, building on its success across Europe and North America.Increased investment in AI: Wiremind designs its own machine learning models and optimisation algorithms, which sit at the core of its clients’ revenue, capacity, inventory and distribution systems. The funding will scale up R&D and add a new layer: large language models (LLMs), both within the decision engine that drives pricing recommendations and in tools that make the platform easier to use.

“Charles and I began our careers in the rail and aviation industries, so we have a unique understanding of the challenges our clients face. It is this first-hand knowledge that we leveraged to grow Wiremind over the years, while staying completely self-financed and investing in our own R&D. Today, we’re accelerating our efforts given the speed at which the market is adopting artificial intelligence tools. This financing round will allow us to reach rapidly growing geographic markets where decisions on technology investments are being made right now,” said Colin Girault-Matz, CEO and Co-Founder of Wiremind.

Wiremind’s flagship product, CAYZN, a revenue management platform whose ARR grew 81% in 2025, is used by more than 20 operators, including Eurostar, National Express, SNCF, Trenitalia and Transavia. PAXONE, its OSDM-native inventory and distribution system, was selected to power France’s new national Intercités ticketing system. EVENTORI, its AI-powered ticketing platform for sports clubs and event organisers, grew 140% in 2025.

Media Contact
Audrey Noel 
Press Relations
audreynoel.medias@gmail.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/wiremind-raises-35-million-in-first-ever-funding-round-302898298.html

Continue Reading

Technology

Ondo Private Markets To Bring Private-Company Exposure Onchain, Starting with AI

Published

on

By

Ondo Finance launches Ondo Private Markets, providing tokenized exposure to leading private companies.The first asset, tokens referencing a leading pre-IPO AI company, is expected to begin secondary market trading this week, with robotics, cybersecurity, biotech, and infrastructure names to follow.Exposure comes through tokenized notes which provide the economic performance of a reference company’s per-share value at a qualifying liquidity event, built on Ondo’s infrastructure with $3.7B in TVL and over 1M holders.

GREENWICH, Conn., Oct. 6, 2026 /PRNewswire/ — Ondo Finance today announced Ondo Private Markets, which will bring tokenized notes delivering the economic performance of industry-defining private companies onchain. Starting with a pre-IPO AI company, the first market will launch this week with permissionless trading available 24/7 on secondary markets. Exposure to leading names across robotics, cybersecurity, biotech, infrastructure, and other sectors will follow as Ondo Private Markets builds out the broadest selection of private-company exposure onchain.

Why it matters

The vast majority of large US companies are private, with 87% exceeding $100 million in annual revenue being privately held. This includes the firms shaping the next generation of technology, meaning retail investors are sidelined for many of today’s largest wealth-creation opportunities. Exposure to leading startups remains largely concentrated among institutions and venture capitalists, and even those who get in can wait years to get out. Private markets have offered neither broad access nor an open exit.

Ondo Private Markets is built to solve both challenges by providing targeted exposure to the world’s top-performing private companies on permissionless blockchain rails where it can trade 24/7 in secondary markets. Eligible investors will be able to enter, exit, or adjust positions anytime, no longer needing to wait for an IPO to realize liquidity. 

How it works

Exposure is provided through tokenized notes, with each note’s payout linked to the per-share value realized on the referenced company’s common shares at a qualifying liquidity event. Further increasing the opportunity for investors, Ondo Private Markets tokens are both freely transferable and composable onchain, enabling them to be transferred or deployed as productive capital across the DeFi ecosystem. 

“In the US, the majority of the investment options accessible for retail are public companies, yet 87% of companies with over $100m in revenue are private. That’s where many of the leaders defining the next era of our economy are emerging, and retail investors can’t access them today. Ondo Private Markets is built to change that, bringing tokenized exposure to the world’s best companies with 24/7 trading on permissionless rails.” — Ian De Bode, Acting CEO and President, at Ondo Finance.

Ondo Private Markets builds on the same institutional-grade infrastructure behind the market-leading platforms for tokenized stocks and Treasuries, which together represent $3.7 billion in total value locked and more than 1 million cumulative holders. It extends Ondo’s mission to make traditional financial assets globally accessible onchain, opening access to an asset class that has long been out of reach for most investors.

About Ondo Finance

Ondo Finance is a blockchain-based technology company focused on tokenizing real-world assets and bringing institutional-quality financial products onchain. By bridging traditional finance and decentralized infrastructure, Ondo aims to make capital markets more accessible, transparent, and efficient.

About Ondo Private Markets

Ondo Private Markets brings private-company exposure onchain. It enables eligible investors in permitted jurisdictions to access tokenized notes designed to provide economic exposure to leading private companies. The notes are obligations of their issuer, not shares in the referenced companies, and provide no ownership or shareholder rights.

DISCLAIMERS AND LIMITATIONS: FOR NON-U.S. PERSONS ONLY. 

Important Information Regarding Token Regulatory and Eligibility Matters: The tokenized assets referenced herein (the “Tokens”) have not been registered under the US Securities Act of 1933, as amended (the “Act”) or the securities or financial instrument laws of any other jurisdiction. The Tokens may not be offered or sold in the United States or to US persons unless registered under the Act or an exemption from the registration requirements thereof is available. 

Persons who place buy orders from within the United States, or any of its states, possessions, territories or federal districts, and persons who are “U.S. persons” or acting for the account or benefit of any “U.S. persons” within the meaning of Rule 902 of Regulation S promulgated under the United States Securities Act of 1933, as amended, are prohibited from subscribing for, acquiring or redeeming the Tokens.

Important Information Regarding the Tokens: The Tokens provide their holders with economic exposure to the value of their underlying assets. However, the Tokens are not themselves stocks and the Tokens do not provide their holders with rights to hold or receive their respective underlying assets. 

The communications herein are only intended for actual or potential business relationships or technical integrations with respect to Tokens. Nothing herein constitutes any offer to sell, or any solicitation of an offer to buy, any assets. Nothing herein constitutes investment, legal, tax or financial advice. Acquiring Tokens involves risks. A holder of Tokens may incur losses, including total loss of their purchase price. Past performance may not be (and for the Tokens will not be) an indication of future results. Investors are responsible for conducting their own research, investigation, verification, checks or consultation for professional or investment advice.

This FAQ is a summary only, is qualified in its entirety by the Token Terms, the Subscription Agreement, and the Token Terms Acceptance and Redemption Claim Certification (collectively, the “Offering Documents”), and does not modify or supplement the Offering Documents. In the event of any conflict, the Token Terms control. Capitalized terms not defined in this FAQ have the meanings given in the Token Terms. Full Offering Documents, Token Terms, and Risk Factors will be provided to eligible clients before subscription and govern in the event of any inconsistency with this summary.

The communications herein may contain forward-looking statements, including, but not limited to, statements regarding future financial performance, business strategies, or expectations for the growth or development of Ondo Finance, PM Issuer Co (BVI) Limited or any of their respective affiliates (each, an “Applicable Entity”). These statements are based on management’s current expectations, estimates, projections, and beliefs, and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those anticipated. Forward-looking statements can be identified by the use of terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other similar expressions. Factors that could cause actual results to differ materially from those contemplated by the forward-looking statements include, but are not limited to, the following: economic, competitive, legal, governmental, and technological factors affecting the operations, markets, products, services, or prices of any Applicable Entity. No Applicable Entity undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Additional terms and restrictions apply. See https://app.ondo.finance/legal-documentation and the Token offering documents for details.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/ondo-private-markets-to-bring-private-company-exposure-onchain-starting-with-ai-302899388.html

SOURCE Ondo Finance

Continue Reading

Technology

GIGABYTE Showcases NVIDIA-Powered AI from Desktop to Enterprise Scale at Ai Everything Abu Dhabi 2026

Published

on

By

ABU DHABI, UAE, Oct. 6, 2026 /PRNewswire/ — GIGABYTE, the world’s leading computer brand, will showcase its latest NVIDIA-powered AI solutions at Ai Everything taking place in Abu Dhabi from October 6 to 7.

GIGABYTE introduces the AI TOP ATOM, a compact personal AI supercomputer based on the NVIDIA DGX Spark platform. Delivering 1 PFLOPS of FP4 performance, it is designed for security, local AI development, fine-tuning, and data science.  

The plug-and-play system offers 1TB to 4TB storage options and supports four-node clustering through a high-speed QSFP switch with 200GbE connectivity per node. Powered by NVIDIA ConnectX-7 networking, the four-node configuration delivers high-bandwidth inter-node communication and provides up to 512GB of aggregate unified system memory for larger and more demanding AI workloads. AI TOP ATOM enables developers and SMBs to build, test, and fine-tune AI models locally, maintaining greater control over sensitive data before scaling workloads to enterprise data centers or the cloud. 

Also on display is the GIGABYTE W775-V10, a high-performance desk-side AI workstation powered by NVIDIA GB300 Grace Blackwell Ultra Desktop Superchip, delivering up to 20 PFLOPS of FP4 performance and 748GB of coherent memory. It supports up to 400 concurrent requests, enabling secure local AI development for regulated data and proprietary models.

“AI development has traditionally required significant cloud investment or shared clusters, putting smaller teams at a disadvantage,” said Jay Lee, GM META at Giga Computing. “This gives teams the ability to develop and test locally, then scale to the data center or cloud when ready. Visit GIGABYTE at Ai Everything Abu Dhabi (Booth H3-04) to experience NVIDIA-powered scalable AI solutions.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/gigabyte-showcases-nvidia-powered-ai-from-desktop-to-enterprise-scale-at-ai-everything-abu-dhabi-2026-302898206.html

Continue Reading

Trending